一分钟看懂
这是一项关于淋巴瘤的I 期 / II 期研究，登记的药物或干预包括Mosunetuzumab (IV)；Tocilizumab；Lenalidomide；Mosunetuzumab (SC)，当前状态为研究进行中，已停止招募。登记地点显示中国长春、成都、上海、天津等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Mosunetuzumab (IV)；Tocilizumab；Lenalidomide；Mosunetuzumab (SC) · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Hospital of Jilin University · 长春
- West China Hospital, Sichuan University · 成都
- Fudan University Shanghai Cancer Center · 上海
- Tianjin Medical University Cancer Institute & Hospital · 天津
- The First Affiliated Hospital of Xiamen University · 厦门
公开的入选条件
- * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- * R/R FL after treatment with at least one prior systemic lymphoma therapy, which includes prior immunotherapy or chemoimmunotherapy
- * Previously untreated participants with FL must require systemic therapy assessed by investigator based on the Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria and have a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2-5
- * Histologically documented FL of Grade 1, 2, or 3a, and that expresses CD20 at time of diagnosis as determined by the local laboratory
- * Fluorodeoxyglucose avid lymphoma (i.e., positron emission tomography (PET) positive lymphoma)
- * At least one bi dimensionally measurable nodal lesion (\>1.5 cm in its largest dimension by PET- computed tomography (CT) scan), or at least one bi dimensionally measurable extranodal lesion (\>1.0 cm in its largest dimension by PET-CT scan)
- * Availability of a representative tumor specimen and the corresponding pathology report for confirmation of the diagnosis of FL
- * Adequate hematologic function (unless due to underlying lymphoma, per the investigator) as defined by the protocol
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04246086；登记信息更新于 2026-09-14。